- About bilaterals.org
- Feb-2016: New ISDS platform launched
- Sep-2004: Launch announcement
- Feb-2015: Relaunch of bilaterals.org
- Mar-2013: Relaunch of bilaterals.org
- Jun-2009: Relaunch of bilaterals.org
- Dec-2008: An update from bilaterals.org and logo design contest announcement
- Dec-2006: bilaterals.org in Spanish & French
- Sep-2006: Update from bilaterals.org
- How to participate
- Key issues
- Texts of agreements
Ranbaxy deal may help India’s entry into Japan
Financial Express | June 14, 2008
Ranbaxy deal may help India’s entry into Japan
New Delhi, Jun 13 — The Daiichi Sankyo-Ranbaxy Laboratories deal has come as a shot in the arm for India’s Comprehensive Economic Co-operation Agreement (CECA) negotiations with Japan. Indian pharma companies have been unable to break into Japan, the world’s second largest drug market, due to the country’s stringent sanitary and phytosanitary standards, technical barriers to trade (TBT) and environmental norms.
"The acquisition of Ranbaxy is arecognition of the quality of Indian drug and other pharma products bytheir Japanese counterparts. Before signing the CECA (Comprehensive Economic Cooperation Agreement), we will now aggressively push the case of our pharma sector as well as that of the chemicals, bio-tech and cosmetics sectors to ensure that Japan agrees to opening up their market for these products," a government official told FE.
Since the current Japanese standards on drugs and other pharmaceuticals products are higher than the accepted international standards, it amounts to a non-tariff barrier, the officialofficial added. India will ask Japan to bring their national standards to international levels and also ensure that there is a harmonization of SPS and TBT standards of both countries.
The government is, however, seeing the Ranbaxy deal as a bigger opportunity apart from getting a foothold in the $65 billion pharma market. In a bid to pave the way for the entry of Indian health industry into Japan, New Delhi would also pitch for relaxing the norms for movement of doctors, nurse and other health professionals from India to Japan.
Indian industry sees Japan’s drug approval procedures as stricter and time-consuming. Besides, it is also mandatory to get such products are tested in Japan itself as they do not accept products tested outside that country.
India would now demand that if the US FDA (Food and Drug Administration) has given approval to a drug, Japan must also allow it without any further testing. The government is also keeping a close watch on the deal’s impact on the Indian pharma market and if it would result in costlier drugs entering the country.
News from the movements
5-Dec-2016 Médecins Sans Frontières
MSF press release: RCEP trade deal negotiators must reject terms that would harm access to medicinesInternational medical humanitarian organisation Médecins Sans Frontières (MSF), along with other health groups, reiterated concerns about harmful intellectual property provisions in the proposed agreement that would increase market monopolies for pharmaceutical corporations and delay or block access to affordable generic medicines.
30-Nov-2016 No al TTIPCientos de organizaciones europeas y canadienses instan a las/los legisladores a votar en contra del Acuerdo Integral de Economía y Comercio (CETA).
30-Nov-2016 Temp.coJelang perundingan perdagangan bebas ASEAN RCEP (Regional Comprehensive Economic Partnership) di Indonesia, organisasi masyarakat sipil dari berbagai negara mulai melayangkan protes kepada pemerintah di negara-negara yang akan menandatangani perjanjian tersebut.
30-Nov-2016Este es un llamamiento urgente de 316 organizaciones de la sociedad civil de los países de Asia y el Pacífico que negocian la Asociación Económica Regional Ampliada para que el contenido tóxico del TPPT no se incorpore al RCEP
29-Nov-2016This is an urgent call by 316 civil society organisations from across the Asian and Pacific countries negotiating the Regional Comprehensive Economic Partnership to reject TPP rules in the RCEP
29-Nov-2016 S2BWe, the undersigned civil society organisations from Canada and Europe, hereby express our deep concern about the Comprehensive Economic and Trade Agreement (CETA) between the EU and Canada.
29-Nov-2016 Collectif Stop TaftaNous organisations de la société civile d’Europe et du Canada, tenons à exprimer ici notre profonde inquiétude par rapport à l’Accord économique et commercial global entre l’Union européenne et le Canada.
22-Nov-2016 Coalition Nationale "Non aux APE"Déshabiller le peuple sénégalais pour subventionner les entreprises européennes. Préparons-nous à refuser toute augmentation ou réduction contre le peuple. Demandons la peine de mort contre l’APE !
bilaterals.org is a collaborative space to share information and support movements struggling against bilateral trade and investment deals which serve corporations, not people. Multilingual. Global. No one owns it. Open publishing. Get involved.